Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Business
  • Published:

Path to approval proves rocky for copycat biodrugs

Nature volume 438, pages 154–155 (2005)Cite this article

Attempts to copy the first generation of biotechnology drugs are facing fierce resistance, as Meredith Wadman reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Meredith Wadman
    View author publications

    You can also search for this author in PubMed Google Scholar

Related links

Related links

Related external links

European Medicine’s Agency (EMEA), guidelines on biosimilars

Datamonitor report on biogenerics

Generic Pharmaceutical Association

Ram Sasisekharan, professor of biological engineering at MIT

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wadman, M. Path to approval proves rocky for copycat biodrugs. Nature 438, 154–155 (2005). https://doi.org/10.1038/438154a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/438154a

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing